Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …

It has been 15 years since the advent of the genome-wide association study (GWAS) era.
Here, we review how this experimental design has realized its promise by facilitating an …

Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype
that we have previously shown to be highly efficient for discovery of genetic associations …

The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …

Background Low-dose corticosteroids have been shown to reduce mortality for patients with
COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation …

Background Immunocompromised patients may be at higher risk of mortality if hospitalised
with Coronavirus Disease 2019 (COVID-19) compared with immunocompetent patients …

The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella
term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity …

Objective Randomized controlled trials comparing tocilizumab and baricitinib in patients with
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …